(EMAILWIRE.COM, September 18, 2019 ) According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach USD 411.1 million by 2022, at a CAGR of 23.1%. The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for non-invasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150106081

In this report, the breast cancer liquid biopsy market is segmented on the basis of circulating biomarker, end user, and region. Based on circulating biomarkers the market is categorised into circulating tumour cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs), and other circulating biomarkers. The cfDNA is the largest and fastest-growing segment in the circulating biomarkers market during the forecast period. The growing research in the field of breast cancer using cfDNA as a means of disease diagnosis and therapeutic monitoring is the major factor contributing to the fast growth and large share of this market.

Based on end user, the breast cancer liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (public health laboratories, pathology laboratories, small molecular laboratories, and research institutes). The reference laboratories segment is expected to register the highest CAGR during the forecast period. The high growth can be attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=150106081

Geographically, the breast cancer liquid biopsy market in the APAC region is expected to register the highest CAGR during the forecast period. Rising disposable incomes in middle-class populations have led to an increase in healthcare spending in India and China. This, along with infrastructural developments and rising penetration of cutting-edge diagnostic technologies in these countries, is a major factor providing significant growth opportunities for manufacturers and distributors of breast cancer liquid biopsy products in this region.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
newsletter@marketsandmarkets.com